Cancer Test Firm Guardant Health Posts Smaller Than Expected Q3 Loss, Lifts Annual Sales Outlook
Precision oncology revenue grew 31%, driven predominantly by increased clinical testing volume and biopharma sample volume, which grew 35% and 11%, respectively.
The company reported 43,900 tests to clinical customers and 7,500 tests to biopharmaceutical customers in the ...
Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.